Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

The Process and Regulatory Components of Inflammation in Brain Oncogenesis.

Mostofa AG, Punganuru SR, Madala HR, Al-Obaide M, Srivenugopal KS.

Biomolecules. 2017 Mar 27;7(2). pii: E34. doi: 10.3390/biom7020034. Review.

2.

A single nucleotide polymorphism in the 3'-UTR of STAT3 regulates its expression and reduces risk of pancreatic cancer in a Chinese population.

Zhu B, Zhu Y, Lou J, Ke J, Zhang Y, Li J, Gong Y, Yang Y, Tian J, Peng X, Zou D, Zhong R, Gong J, Chang J, Li L, Miao X.

Oncotarget. 2016 Sep 20;7(38):62305-62311. doi: 10.18632/oncotarget.11607.

3.

PDGFRα depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signals.

Cenciarelli C, Marei HE, Felsani A, Casalbore P, Sica G, Puglisi MA, Cameron AJ, Olivi A, Mangiola A.

Oncotarget. 2016 Aug 16;7(33):53047-53063. doi: 10.18632/oncotarget.10132. Erratum in: Oncotarget. 2017 May 30;8(22):36931.

4.

Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.

Jahani-Asl A, Yin H, Soleimani VD, Haque T, Luchman HA, Chang NC, Sincennes MC, Puram SV, Scott AM, Lorimer IA, Perkins TJ, Ligon KL, Weiss S, Rudnicki MA, Bonni A.

Nat Neurosci. 2016 Jun;19(6):798-806. doi: 10.1038/nn.4295. Epub 2016 Apr 25.

5.

Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.

Stringer BW, Bunt J, Day BW, Barry G, Jamieson PR, Ensbey KS, Bruce ZC, Goasdoué K, Vidal H, Charmsaz S, Smith FM, Cooper LT, Piper M, Boyd AW, Richards LJ.

Oncotarget. 2016 May 17;7(20):29306-20. doi: 10.18632/oncotarget.8720.

6.

Association between Prediagnostic Allergy-Related Serum Cytokines and Glioma.

Schwartzbaum J, Seweryn M, Holloman C, Harris R, Handelman SK, Rempala GA, Huang RP, Burkholder B, Brandemihl A, Kallberg H, Johannesen TB, Ahlbom A, Feychting M, Grimsrud TK.

PLoS One. 2015 Sep 9;10(9):e0137503. doi: 10.1371/journal.pone.0137503. eCollection 2015.

7.

Inositol Polyphosphate-5-Phosphatase F (INPP5F) inhibits STAT3 activity and suppresses gliomas tumorigenicity.

Kim HS, Li A, Ahn S, Song H, Zhang W.

Sci Rep. 2014 Dec 5;4:7330. doi: 10.1038/srep07330.

8.

Emerging insights into barriers to effective brain tumor therapeutics.

Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H.

Front Oncol. 2014 Jul 21;4:126. doi: 10.3389/fonc.2014.00126. eCollection 2014. Review.

9.

Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.

Furcht CM, Buonato JM, Skuli N, Mathew LK, Muñoz Rojas AR, Simon MC, Lazzara MJ.

J Cell Sci. 2014 Aug 15;127(Pt 16):3555-67. doi: 10.1242/jcs.150862. Epub 2014 Jun 20.

10.

The Role of STAT3 in Thyroid Cancer.

Sosonkina N, Starenki D, Park JI.

Cancers (Basel). 2014 Mar 6;6(1):526-44. doi: 10.3390/cancers6010526.

11.

Bufalin induces the interplay between apoptosis and autophagy in glioma cells through endoplasmic reticulum stress.

Shen S, Zhang Y, Wang Z, Liu R, Gong X.

Int J Biol Sci. 2014 Feb 6;10(2):212-24. doi: 10.7150/ijbs.8056. eCollection 2014.

12.

STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications.

Kim JE, Patel M, Ruzevick J, Jackson CM, Lim M.

Cancers (Basel). 2014 Feb 10;6(1):376-95. doi: 10.3390/cancers6010376.

13.

Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms.

Cruceru ML, Neagu M, Demoulin JB, Constantinescu SN.

J Cell Mol Med. 2013 Oct;17(10):1218-35. doi: 10.1111/jcmm.12122. Epub 2013 Sep 2. Review.

14.

Blockade of glioma proliferation through allosteric inhibition of JAK2.

He K, Qi Q, Chan CB, Xiao G, Liu X, Tucker-Burden C, Wang L, Mao H, Lu X, McDonald FE, Luo H, Fan QW, Weiss WA, Sun SY, Brat DJ, Ye K.

Sci Signal. 2013 Jul 9;6(283):ra55. doi: 10.1126/scisignal.2003900.

15.

Brain tumor stem cells: Molecular characteristics and their impact on therapy.

Schonberg DL, Lubelski D, Miller TE, Rich JN.

Mol Aspects Med. 2014 Oct;39:82-101. doi: 10.1016/j.mam.2013.06.004. Epub 2013 Jul 4. Review.

16.
17.

iNOS: a potential therapeutic target for malignant glioma.

Jahani-Asl A, Bonni A.

Curr Mol Med. 2013 Sep;13(8):1241-9. Review.

18.

ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro.

Xiong J, Zhou L, Yang M, Lim Y, Zhu YH, Fu DL, Li ZW, Zhong JH, Xiao ZC, Zhou XF.

Neuro Oncol. 2013 Aug;15(8):990-1007. doi: 10.1093/neuonc/not039. Epub 2013 Apr 10.

19.

Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.

Carra E, Barbieri F, Marubbi D, Pattarozzi A, Favoni RE, Florio T, Daga A.

Cell Cycle. 2013 Feb 1;12(3):491-500. doi: 10.4161/cc.23372. Epub 2013 Jan 16.

20.

DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.

Televantou D, Karkavelas G, Hytiroglou P, Lampaki S, Iliadis G, Selviaridis P, Polyzoidis KS, Fountzilas G, Kotoula V.

Pathol Oncol Res. 2013 Apr;19(2):329-43. doi: 10.1007/s12253-012-9588-7. Epub 2012 Dec 20.

Supplemental Content

Support Center